Market Currents
While multiple-sclerosis patients have waited years for pills to be developed to treat the...
-
Tuesday, November 20, 2012, 9:20 AM ETWhile multiple-sclerosis patients have waited years for pills to be developed to treat the debilitating disease, doctors are warning them to be wary. That's because drugs such as Novartis' (NVS) Gilenya and Sanofi's (SNY) Aubagio can have significant side-effects. All of which is positive for Teva (TEVA), whose Copaxone is injected rather than taken orally.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
